News Image

Jyong Biotech Expands Regional Partnerships, Signs MOU with a Vietnam Pharmaceutical Distributor for MCS‑2 Market Entry

Provided By GlobeNewswire

Last update: Dec 4, 2025

New Taipei City, Taiwan, Dec. 04, 2025 (GLOBE NEWSWIRE) -- Jyong Biotech Ltd. (Nasdaq: MENS) (the “Company” or “Jyong Biotech”), a science-driven biotechnology company based in Taiwan committed to developing and commercializing innovative and differentiated new drugs (plant-derived) mainly specializing in the treatment of urinary system diseases, with an initial focus on the markets of the U.S., the EU and Asia, today announced that it has entered into a non-binding Memorandum of Understanding (the “MOU”) with a Vietnam‑based pharmaceutical distribution company headquartered in Ho Chi Minh City, to evaluate the development and commercialization of MCS‑2 in the Vietnam pharmaceutical market.

Read more at globenewswire.com

JYONG BIOTECH LTD

NASDAQ:MENS (12/5/2025, 8:00:00 PM)

29.2

+0.01 (+0.03%)



Find more stocks in the Stock Screener

Follow ChartMill for more